Impact of use of oral anticancer drugs on activity of Italian oncology practices: Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)

Stefania Gori, Massimo Di Maio, Carmine Pinto, Oscar Alabiso, Editta Baldini, Enrico Barbato, Giordano Domenico Beretta, Stefano Bravi, Orazio Caffo, Luciano Canobbio, Francesco Carrozza, Saverio Cinieri, Giorgio Cruciani, Angelo Dinota, Vittorio Gebbia, Lucio Giustini, Claudio Graiff, Annamaria Molino, Antonio Muggiano, Giuliano PandoliFabio Puglisi, Pierosandro Tagliaferri, Silverio Tomao, Gianluigi Lunardi, Marco Venturini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims and background. In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices. Methods and study design. A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in the management of patients treated with these drugs; (3) issues related to treatment costs and reimbursement procedures. Results. Thirty-six questionnaires were received from institutions distributed throughout the Italian territory. Oral anticancer drugs (both chemotherapy and molecularly targeted agents) accounted for a significant proportion (17%) of prescribed treatments. Among the responding institutions, there were different dispensation procedures of oral drugs to patients: drugs were dispensed by the pharmacist (57%) or directly by the medical oncologist (23%) or nurse (20%). The medical oncologist played a major role in the communication with patients (73% alone and a further 24% in cooperation with other professional figures) and was the point of reference in the event of side effects in 97% of cases. In most cases, the reimbursement of drug costs was separated ("File F" procedure) from the flat fare received by the hospital for outpatient visits or day-hospital access. Conclusions. Optimal organization of oral anticancer treatment warrants the cooperation and integration of multiple professional figures. At least three figures are involved in patient management in the hospital: the medical oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments are associated with specific reimbursement issues: in the majority of cases, the cost of the drug is reimbursed separately from the cost of patient access.

Original languageEnglish
Pages (from-to)35-38
Number of pages4
JournalTumori
Volume99
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Medical Oncology
Pharmaceutical Preparations
Drug Costs
Pharmacists
Nurses
Surveys and Questionnaires
Health Care Costs
Outpatients
Therapeutics
Communication
Organizations
Costs and Cost Analysis
Drug Therapy
Oncologists

Keywords

  • Drug dispensation
  • Oral anticancer drugs
  • Reimbursement

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Impact of use of oral anticancer drugs on activity of Italian oncology practices : Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). / Gori, Stefania; Di Maio, Massimo; Pinto, Carmine; Alabiso, Oscar; Baldini, Editta; Barbato, Enrico; Beretta, Giordano Domenico; Bravi, Stefano; Caffo, Orazio; Canobbio, Luciano; Carrozza, Francesco; Cinieri, Saverio; Cruciani, Giorgio; Dinota, Angelo; Gebbia, Vittorio; Giustini, Lucio; Graiff, Claudio; Molino, Annamaria; Muggiano, Antonio; Pandoli, Giuliano; Puglisi, Fabio; Tagliaferri, Pierosandro; Tomao, Silverio; Lunardi, Gianluigi; Venturini, Marco.

In: Tumori, Vol. 99, No. 1, 01.2013, p. 35-38.

Research output: Contribution to journalArticle

Gori, S, Di Maio, M, Pinto, C, Alabiso, O, Baldini, E, Barbato, E, Beretta, GD, Bravi, S, Caffo, O, Canobbio, L, Carrozza, F, Cinieri, S, Cruciani, G, Dinota, A, Gebbia, V, Giustini, L, Graiff, C, Molino, A, Muggiano, A, Pandoli, G, Puglisi, F, Tagliaferri, P, Tomao, S, Lunardi, G & Venturini, M 2013, 'Impact of use of oral anticancer drugs on activity of Italian oncology practices: Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)', Tumori, vol. 99, no. 1, pp. 35-38. https://doi.org/10.1700/1248.13785
Gori, Stefania ; Di Maio, Massimo ; Pinto, Carmine ; Alabiso, Oscar ; Baldini, Editta ; Barbato, Enrico ; Beretta, Giordano Domenico ; Bravi, Stefano ; Caffo, Orazio ; Canobbio, Luciano ; Carrozza, Francesco ; Cinieri, Saverio ; Cruciani, Giorgio ; Dinota, Angelo ; Gebbia, Vittorio ; Giustini, Lucio ; Graiff, Claudio ; Molino, Annamaria ; Muggiano, Antonio ; Pandoli, Giuliano ; Puglisi, Fabio ; Tagliaferri, Pierosandro ; Tomao, Silverio ; Lunardi, Gianluigi ; Venturini, Marco. / Impact of use of oral anticancer drugs on activity of Italian oncology practices : Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). In: Tumori. 2013 ; Vol. 99, No. 1. pp. 35-38.
@article{30f1f8c172b94ee4a7638e3d06a81ec4,
title = "Impact of use of oral anticancer drugs on activity of Italian oncology practices: Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)",
abstract = "Aims and background. In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices. Methods and study design. A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in the management of patients treated with these drugs; (3) issues related to treatment costs and reimbursement procedures. Results. Thirty-six questionnaires were received from institutions distributed throughout the Italian territory. Oral anticancer drugs (both chemotherapy and molecularly targeted agents) accounted for a significant proportion (17{\%}) of prescribed treatments. Among the responding institutions, there were different dispensation procedures of oral drugs to patients: drugs were dispensed by the pharmacist (57{\%}) or directly by the medical oncologist (23{\%}) or nurse (20{\%}). The medical oncologist played a major role in the communication with patients (73{\%} alone and a further 24{\%} in cooperation with other professional figures) and was the point of reference in the event of side effects in 97{\%} of cases. In most cases, the reimbursement of drug costs was separated ({"}File F{"} procedure) from the flat fare received by the hospital for outpatient visits or day-hospital access. Conclusions. Optimal organization of oral anticancer treatment warrants the cooperation and integration of multiple professional figures. At least three figures are involved in patient management in the hospital: the medical oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments are associated with specific reimbursement issues: in the majority of cases, the cost of the drug is reimbursed separately from the cost of patient access.",
keywords = "Drug dispensation, Oral anticancer drugs, Reimbursement",
author = "Stefania Gori and {Di Maio}, Massimo and Carmine Pinto and Oscar Alabiso and Editta Baldini and Enrico Barbato and Beretta, {Giordano Domenico} and Stefano Bravi and Orazio Caffo and Luciano Canobbio and Francesco Carrozza and Saverio Cinieri and Giorgio Cruciani and Angelo Dinota and Vittorio Gebbia and Lucio Giustini and Claudio Graiff and Annamaria Molino and Antonio Muggiano and Giuliano Pandoli and Fabio Puglisi and Pierosandro Tagliaferri and Silverio Tomao and Gianluigi Lunardi and Marco Venturini",
year = "2013",
month = "1",
doi = "10.1700/1248.13785",
language = "English",
volume = "99",
pages = "35--38",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of use of oral anticancer drugs on activity of Italian oncology practices

T2 - Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)

AU - Gori, Stefania

AU - Di Maio, Massimo

AU - Pinto, Carmine

AU - Alabiso, Oscar

AU - Baldini, Editta

AU - Barbato, Enrico

AU - Beretta, Giordano Domenico

AU - Bravi, Stefano

AU - Caffo, Orazio

AU - Canobbio, Luciano

AU - Carrozza, Francesco

AU - Cinieri, Saverio

AU - Cruciani, Giorgio

AU - Dinota, Angelo

AU - Gebbia, Vittorio

AU - Giustini, Lucio

AU - Graiff, Claudio

AU - Molino, Annamaria

AU - Muggiano, Antonio

AU - Pandoli, Giuliano

AU - Puglisi, Fabio

AU - Tagliaferri, Pierosandro

AU - Tomao, Silverio

AU - Lunardi, Gianluigi

AU - Venturini, Marco

PY - 2013/1

Y1 - 2013/1

N2 - Aims and background. In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices. Methods and study design. A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in the management of patients treated with these drugs; (3) issues related to treatment costs and reimbursement procedures. Results. Thirty-six questionnaires were received from institutions distributed throughout the Italian territory. Oral anticancer drugs (both chemotherapy and molecularly targeted agents) accounted for a significant proportion (17%) of prescribed treatments. Among the responding institutions, there were different dispensation procedures of oral drugs to patients: drugs were dispensed by the pharmacist (57%) or directly by the medical oncologist (23%) or nurse (20%). The medical oncologist played a major role in the communication with patients (73% alone and a further 24% in cooperation with other professional figures) and was the point of reference in the event of side effects in 97% of cases. In most cases, the reimbursement of drug costs was separated ("File F" procedure) from the flat fare received by the hospital for outpatient visits or day-hospital access. Conclusions. Optimal organization of oral anticancer treatment warrants the cooperation and integration of multiple professional figures. At least three figures are involved in patient management in the hospital: the medical oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments are associated with specific reimbursement issues: in the majority of cases, the cost of the drug is reimbursed separately from the cost of patient access.

AB - Aims and background. In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices. Methods and study design. A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in the management of patients treated with these drugs; (3) issues related to treatment costs and reimbursement procedures. Results. Thirty-six questionnaires were received from institutions distributed throughout the Italian territory. Oral anticancer drugs (both chemotherapy and molecularly targeted agents) accounted for a significant proportion (17%) of prescribed treatments. Among the responding institutions, there were different dispensation procedures of oral drugs to patients: drugs were dispensed by the pharmacist (57%) or directly by the medical oncologist (23%) or nurse (20%). The medical oncologist played a major role in the communication with patients (73% alone and a further 24% in cooperation with other professional figures) and was the point of reference in the event of side effects in 97% of cases. In most cases, the reimbursement of drug costs was separated ("File F" procedure) from the flat fare received by the hospital for outpatient visits or day-hospital access. Conclusions. Optimal organization of oral anticancer treatment warrants the cooperation and integration of multiple professional figures. At least three figures are involved in patient management in the hospital: the medical oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments are associated with specific reimbursement issues: in the majority of cases, the cost of the drug is reimbursed separately from the cost of patient access.

KW - Drug dispensation

KW - Oral anticancer drugs

KW - Reimbursement

UR - http://www.scopus.com/inward/record.url?scp=84878215440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878215440&partnerID=8YFLogxK

U2 - 10.1700/1248.13785

DO - 10.1700/1248.13785

M3 - Article

C2 - 23548997

AN - SCOPUS:84878215440

VL - 99

SP - 35

EP - 38

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -